Anticoagulation Management in Atrial Fibrillation Patients Aged 80 and Above

Introduction to Anticoagulation in Atrial Fibrillation

The American Heart Association recommends that patients with atrial fibrillation and a CHA₂DS₂-VASc score of 2 or higher should receive oral anticoagulation, as the annual stroke risk exceeds 2.5% per year 1, 2, 3
Approximately 25% of all strokes in patients aged 80 and above are attributable to atrial fibrillation, making this the single most important preventable cause of stroke in this age group 2, 3
Oral anticoagulation reduces stroke risk by 60-65% compared to no treatment, and by 45% compared to aspirin alone, in patients with atrial fibrillation 2, 3

The American College of Cardiology states that age per se is not a contraindication to the anticoagulation of high-risk atrial fibrillation patients, as the absolute benefit of stroke prevention exceeds bleeding risk in the vast majority of cases 4, 5
Anticoagulation remains warranted if the ischemic stroke risk without anticoagulation exceeds the bleeding risk with anticoagulation—a threshold easily met at age 80 4, 5
The 2014 AHA/ACC/HRS guideline strongly recommends oral anticoagulation for CHA₂DS₂-VASc ≥2 (Class I, Level A) 1

The European Society of Cardiology recommends a reduced dose of dabigatran 110 mg twice daily may be considered in patients over 75 years to reduce bleeding risk (Class IIb, Level B) 6, 7
However, dose reduction should be based on bleeding risk assessment, not age alone—the standard 150 mg twice daily dose remains appropriate for most patients without high bleeding risk 6, 7

Renal function assessment at least annually is mandatory (Class I, Level B), as renal impairment increases bleeding risk and dabigatran is 80% renally cleared 1
Blood pressure control is necessary to reduce both ischemic stroke risk and intracranial hemorrhage risk during anticoagulation 6, 7, 5
Verification of appropriate dosing is crucial: standard dose is 150 mg twice daily; reduce to 110 mg twice daily if age over 75 years AND additional bleeding risk factors present 6, 7

Oral anticoagulation should only be interrupted or stopped in specific circumstances, such as active severe bleeding, severe renal impairment, or documented intolerance 6, 7, 1
After a bleeding event, reinitiation of anticoagulation should be considered by a multidisciplinary team after addressing reversible bleeding causes (Class IIa, Level B) 6, 7

The American College of Chest Physicians suggests that the benefits of stroke prevention with oral anticoagulation far outweigh the bleeding risks from falls in elderly patients with atrial fibrillation, and fall risk alone should not be a reason to withhold anticoagulation, with a patient needing to fall 295 times per year before the risk of subdural hemorrhage from falls outweighs the stroke prevention benefit of anticoagulation 8
The American Heart Association/American Stroke Association indicates that age per se is not a contraindication to anticoagulation in high-risk atrial fibrillation patients, as the stroke prevention benefit exceeds bleeding risk in the vast majority of cases, with elderly patients having approximately twice the bleeding risk during anticoagulation compared to younger patients 9

The American College of Chest Physicians recommends that before initiating anticoagulation, implement fall prevention strategies rather than withholding therapy, including providing walking aids and appropriate footwear, conducting home review to remove trip hazards, and performing neurological assessment if falls are unexplained 8
The American College of Chest Physicians suggests avoiding concomitant antiplatelet therapy (aspirin or NSAIDs) unless there is a compelling indication, as these medications increase bleeding risk without additional stroke benefit in AF 8
The American Heart Association/American Stroke Association recommends that for warfarin, the target INR should be 2.0-3.0 for most patients, with some experts recommending a target INR 2.0 (range 1.6-2.5) for primary prevention in patients >75 years to minimize bleeding risk 9

The American College of Chest Physicians states that in patients with cognitive impairment or dementia, anticoagulation should only be withheld if there is no available caregiver who can guarantee medication adherence 8